BMG Pharma is a specialty pharma company specialized in development, registration and commercial partnership of innovative, state-of-the-art biotechnological products.
BMG Pharma is challenging the hyaluronic acid market. The Hyaluromimethic® technology is the innovative and patented platform for the creation of wide range of biomaterials for medical applications.
Now, BMG Pharma is focalizing on the aesthetic medicine market.
BMG Pharma exploits its strong expertise in specific therapeutic areas to meet the needs of patients and provide high quality, effective and safe solutions.
BMG Pharma is headquartered in Milan and the biomaterials R&D and Production plant is in Torviscosa (UD).
Internationally, BMG Pharma extends its presence in more than 60 countries through its partners marketing products in Europe, the Middle East, Asia and Latin America.
